Its clinical management is strongly influenced by molecular heterogeneity, with major subtypes including hormone Luminal, HER2-positive (HER2+), and triple-negative breast cancer (TNBC), each showing distinct therapeutic vulnerabilities [3]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.